AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05694897 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae block using bupivacaine and dememdetomidine
Description: After induction of general anesthesia the patients will be flipped to the prone position and ESP block was performed using, a high frequency linear ultrasound probe placed longitudinally 2 to 3 cm lateral to the 10th thoracic vertebrae, and the trapezius and erector Spinae muscles identified.~An 18-G Tuohy needle passed along the plane of the transducer until its tip hit the transverse process of T10; the needle was then withdrawn slightly.~Total volume of 25 ml was injected including 20 mL 0.25% bupivacaine plus dexmedetomidine 1ug/kg.
Study NCT06160622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leritrelvir
Description: Oral
Study NCT04683809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Patients will attend rehabilitation sessions through online programmes for rehabilitation
Study NCT06459830 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mime Therapy with Neural Mobilization
Description: Experimental group will receive mime therapy and neural mobilization session with small resting intervals.~Self- facial massages for 10 minutes. Breathing and relaxation exercises for 5 mins. Exercises to enhance coordination between both sides of the face and to reduce synkinesis.~Exercises to assist with eye and lip closure for 5 mins. Articulation Exercises for 5 mins. Facial expression exercises for 10 mins.~Facial Neural Mobilization:~Facial mobilization technique will apply when the patient in supine position with head on the table in neural rotation.~The circular movement and horizontal traction will be applied 25 times in three sets with a 5-second rest period in between a single manipulation and a 30- second rest period in between the sets.~All the participates in the experimental group will receive 15 treatment sessions. Each session will held for 60 minutes per day, 5 days per week, for total duration of 3 weeks.
Study NCT06459830 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mime Therapy with Placebo Mobilization
Description: Control group will receive mime therapy and placebo nerve mobilization session with small resting intervals.~Self- facial massages for 10 minutes. Breathing and relaxation exercises for 5 mins. Exercises to enhance coordination between both sides of the face and to reduce synkinesis.~Exercises to assist with eye and lip closure for 5 mins. Articulation Exercises for 5 mins. Facial expression exercises for 10 mins.~Placebo Nerve Mobilization Technique:~The placebo nerve mobilization followed all the procedures of real nerve mobilization without applying horizontal and circular auricular traction. The purpose of this placebo nerve mobilization is not to deprived the control group from therapy and equalize the time duration of treatment protocol.~All the participates in the control group will receive 15 treatment sessions. Each session will held for 60 minutes per day, 5 days per week, for total duration of 3 weeks.
Study NCT05486442 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT for weight-related experiential avoidance
Description: Participants in the experimental group received weight concern-related ACT training in a group setting. Each session focused on different dimensions of ACT and included relevant exercises and homeworks. Dimensions studied included creative hopelessness, control strategies, mindfulness exercises, values and barries to values and commitment to action.
Study NCT06459895 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Long non-coding MALAT1 gene expression assay:
Description: RNA extraction (isolation from whole blood) II-Synthesis of CDNA from RNA by reverse transcription III-Gene expression assay by RT-PCR reaction
Study NCT04787471 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: 30 minute photoactivation of riboflavin 0.1%
Description: Use of riboflavin 0.1% eye drops and 3mW/cm2 UVA light for 30 minutes
Study NCT04787471 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: 10 minute photoactivation of riboflavin 0.1%
Description: Use of riboflavin 0.1% eye drops and 9mW/cm2 UVA light for 10 minutes
Study NCT05110846 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04238299 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Multiparametric renal MRI
Description: Localiser scans; Kidney volume; Longitudinal (T1) relaxation time mapping; Diffusion weighted imaging (DWI); Phase Contrast MRI; Arterial spin labelling (ASL); Blood Oxygen Level Dependent (BOLD) mapping
Study NCT05422742 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SRP + MM
Description: Subjects will be randomized into either SRP only or SRP +MM. Periodontal therapy will consist of one visit full-month SRP alone or in-combination with MM placed at all sites regardless of probing pocket depth. Each site will recieve 1mg of MM for a total of 6mg of MM per tooth.
Study NCT05422742 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and Root Planing (SRP)
Description: Procedure involving removal of dental plaque and calculus (scaling or debridement) and then smoothing, or planing, of the (exposed) surfaces of the roots, removing cementum or dentine that is impregnated with calculus, toxins, or microorganisms, the etiologic agents that cause inflammation.
Study NCT04919044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Imagery Training
Description: The number of imagined contractions were 34 trials, each trial was 10 seconds with 5seconds rest between each trial and 2 minutes' rest was given after first 17 trials.
Study NCT04130958 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Theta Burst Transcranial Magnetic Stimulation (Active)
Description: iTBS-TMS is a noninvasive neuromodulation technique that uses a powerful magnet to induce focal electrical currents in target brain regions.
Study NCT05110846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-868
Description: CT-868
Study NCT04130958 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Intermittent Theta Burst Transcranial Magnetic Stimulation (Sham)
Description: The sham version of iTBS-TMS involves placing the magnet over the same target brain region but the device will not be turned on during the treatment. There will be two electrodes placed on the scalp that mimic the sensation of iTBS-TMS but does not induce focal electrical currents.
Study NCT04488003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulixertinib
Description: Oral, 600 mg, twice daily, for 28-days in each treatment cycle
Study NCT04488003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Physician's Choice
Description: Physician's choice will be restricted to two approved (not off-label) treatments for each tumor histology (agents targeting BRAF or MEK kinases and experimental agents are not permitted as physician choice)).
Study NCT05069025 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music
Description: In the music group, music chosen by the participant will be played through a speaker by the nursing staff during outpatient hysteroscopy. Music will be played through a speaker instead of headphones in order to maintain good communication and interaction between the participant and the doctor.
Study NCT05069025 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: no-music
Description: Participants in the non-music group will undergo outpatient hysteroscopy in the same setting and standard procedure without listening to any music.
Study NCT04659278 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Endourage 1200 mg OMD ™ Oral Mucosal Drops
Description: The CBD/THC ratio of OMD 1200 is 14:1 and the CBD/Terpene ratio is 1:1. Each ¼ dropper contains 10.2 mg of CBD and 0.7 mg of THC. The total % THC is 0.28%. These ratios indicate that the product will not cause euphoria.
Study NCT04659278 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Endourage 1200 mg OMD ™ Oral Mucosal Drops
Description: The CBD/THC ratio of OMD 1200 is 14:1 and the CBD/Terpene ratio is 1:1. Each ¼ dropper contains 10.2 mg of CBD and 0.7 mg of THC. The total % THC is 0.28%. These ratios indicate that the product will not cause euphoria.
Study NCT04659278 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Isolate
Description: The isolate formulation contains 0% cannabinoids (CBD 0.00%; CBDa 0.00%; detla 9 THC 0.00%; THCa 0.00%).
Study NCT04659278 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Isolate
Description: The isolate formulation contains 0% cannabinoids (CBD 0.00%; CBDa 0.00%; detla 9 THC 0.00%; THCa 0.00%).
Study NCT04659278 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Total CBD = CBD + (CBD-A \* 0.877). Total THC = THCA-A \* 0.877 + Delta 9 THC, ND = \<LOQ, T-Caryophyllene = Trans-Caryophyllene, \<LOQ = Less Than Limit of Quantitation, QNS = Quantity Not Sufficient. (%) = Percent, (ppm) = Parts per Million, (ppb) = Parts per Billion, (μg/Kg) = Microgram per Kilogram, (mg/g) = Milligram per Gram, ppm = (μg/g), ppb = (μg/kg),
Study NCT04659278 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Total CBD = CBD + (CBD-A \* 0.877). Total THC = THCA-A \* 0.877 + Delta 9 THC, ND = \<LOQ, T-Caryophyllene = Trans-Caryophyllene, \<LOQ = Less Than Limit of Quantitation, QNS = Quantity Not Sufficient. (%) = Percent, (ppm) = Parts per Million, (ppb) = Parts per Billion, (μg/Kg) = Microgram per Kilogram, (mg/g) = Milligram per Gram, ppm = (μg/g), ppb = (μg/kg),
Study NCT04659278 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Total CBD = CBD + (CBD-A \* 0.877). Total THC = THCA-A \* 0.877 + Delta 9 THC, ND = \<LOQ, T-Caryophyllene = Trans-Caryophyllene, \<LOQ = Less Than Limit of Quantitation, QNS = Quantity Not Sufficient. (%) = Percent, (ppm) = Parts per Million, (ppb) = Parts per Billion, (μg/Kg) = Microgram per Kilogram, (mg/g) = Milligram per Gram, ppm = (μg/g), ppb = (μg/kg),
Study NCT04659278 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Peppermint Oil, masking flavor
Description: Mentha piperita Leaf /Stem Oil; Physical state: Liquid. Color: Colorless to pale yellow; Characteristic peppermint odor; Not dangerous goods.
Study NCT04659278 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Peppermint Oil, masking flavor
Description: Mentha piperita Leaf /Stem Oil; Physical state: Liquid. Color: Colorless to pale yellow; Characteristic peppermint odor; Not dangerous goods.
Study NCT04659278 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Peppermint Oil, masking flavor
Description: Mentha piperita Leaf /Stem Oil; Physical state: Liquid. Color: Colorless to pale yellow; Characteristic peppermint odor; Not dangerous goods.
Study NCT05872867 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WM-A1-3389
Description: Anti-IGSF1 (Immunoglobulin superfamily member 1)
Study NCT05872867 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Anti-PD-1(Programmed cell death protein 1)
Study NCT05599087 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Acellular system
Description: Regenerative Endodontic Procedure Tissue engineering procedure
Study NCT04713592 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Risankizumab
Description: Subcutaneous (SC) Injection
Study NCT04713592 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Risankizumab
Description: Subcutaneous (SC) Injection
Study NCT04713592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous (SC) Injection
Study NCT04960553 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exufiber® and Mepilex® Border Flex
Description: Post Market Clinical Follow-up Investigation applying Exufiber® and Mepilex® Border Flex to 102 subjects who meet the study criteria for up to 12 weeks
Study NCT04359030 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Multislice CT scanning for aortic wall calcification
Description: Multislice CT scanning for aortic wall calcification
Study NCT06396923 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Wingate test
Description: Wingate Anaerobic Power Test is based on maximal pedaling on a bicycle ergometer against a predetermined constant load to provide the highest mechanical power for 30 seconds. During the test, measurements are made automatically at intervals of five seconds and six equal intervals. As a result of these measurements, some data are obtained that allow us to obtain information about anaerobic performance.
Study NCT06396923 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Wingate test
Description: Wingate Anaerobic Power Test is based on maximal pedaling on a bicycle ergometer against a predetermined constant load to provide the highest mechanical power for 30 seconds. During the test, measurements are made automatically at intervals of five seconds and six equal intervals. As a result of these measurements, some data are obtained that allow us to obtain information about anaerobic performance.
Study NCT04359030 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic stress echocardiography
Description: Transthoracic stress echocardiography
Study NCT05975437 — intervention group
Intervention type: OTHER
Intervention: personalized surveillance plans (PSP) and personalized aftercare plans (PAP)
Description: The PSP contains decisions on the surveillance trajectory based on individual risks and needs, assessed with the 'Breast Cancer Surveillance Decision Aid' including the INFLUENCE prediction tool. The PAP contains decisions on the aftercare trajectory based on individual needs and preferences and available care resources, which decision-making is supported by a patient decision aid.
Study NCT06315803 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real-time 3D Xplane ultrasound
Description: After the puncture needle is in the skin, the longitudinal section of the Xplane mode can be adjusted to keep the needle in the proposed plane.
Study NCT05423327 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: No Intervention
Description: Single blood draw
Study NCT06018896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbate
Description: For patients with baseline serum Vitamin C concentration \< 65 μmol/L, intravenous Vitamin C 10 g × 7 days, intravenous Vitamin C 4 g × 7 days, intravenous Vitamin C 2 g × 7 days, followed by continuously 900 mg/day, three times a day, orally. For patients with baseline serum Vitamin C concentration ≥ 65 μmol/L, continuously 900 mg/day, three times a day, orally.
Study NCT06073054 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Research Pharmacist
Description: The goal of this intervention is to determine if contact with the research pharmacist will improve the health of the mother and/or child.
Study NCT05981963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-BMS-986196
Description: Specified dose on specified days
Study NCT04923230 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cannabis Actions and Practices Resource for Parents
Description: The Cannabis Actions and Practices (CAP) resource is a parent-focused approach to help MM parents address marijuana use and attitudes by their adolescents. CAP includes information about the effects of marijuana on adolescent behavioral health, brain development, and social functioning. CAP also integrates motivational strategies to foster The CAP intervention focuses on building parenting skills and teaching strategies to: (1) limit adolescent exposure to cannabis products and parent cannabis use at home, (2) improve parent communication about their MM use, expectations about youth marijuana use, and attitudes about the potential harms of adolescent cannabis use, (3) improve monitoring, and (4) increase positive reinforcement for youth abstinence. Parents meet with an interventionist for two individual 75-minute sessions involving presentations, discussions, and behavioral rehearsal of key parenting skills.
Study NCT05434117 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity interval Nordic walking
Description: Participants will complete supervised exercise sessions twice weekly for 10 weeks. Exercise specialists will educate participants in proper use of walking poles and basic Nordic walking techniques and supervise the exercise training sessions. HIIT-NoW will be 45 min in duration using Nordic poles and consists of (i) a 10-min warm-up at 30-59% heart rate reserve (HRR, light-to-moderate intensity); (ii) 4 × 4 min of high-intensity work periods at 60-89% HRR (vigorous intensity) interspersed with 3 min of low-intensity work periods at 30-59% HRR (light-to-moderate intensity); and, (iii) a 10-min cooldown at 30-39% HRR (light intensity). To allow participants to acclimatize to the HIIT-NoW protocol, the training intensity will target 60-69% HRR for the first week, 70-79% HRR in the second week, and 80-89% HRR from the third week onward. If participants do not tolerate 89% HRR well, they will exercise as close to 89% HRR as possible.
Study NCT05434117 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard cardiovascular rehabilitation
Description: Individuals assigned to standard CR will attend onsite exercise-based CR comprised of one onsite exercise session per week for 8-10 weeks. The onsite CR offers exercise sessions tailored to the fitness of patients and strengthening exercise.
Study NCT05773014 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Speculum Exams
Description: Same as arm
Study NCT05773014 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Digital Exams
Description: Same as arm
Study NCT05243381 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 20 ml blood test
Description: 20 ml blood test
Study NCT05834036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin Oral Capsule
Description: Amoxicillin 875mg every 12 hours for 7 days.
Study NCT04723043 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mechanical ventilation modes
Description: ventilation with pressure controlled mode in laparoscopic abdominal surgery ventilation with volume controlled mode in laparoscopic abdominal surgery
Study NCT05739435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESK-001
Description: Oral tablet
Study NCT06100055 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rectal Irrigation
Description: Rectal irrigation is the introduction of warm tap water through the anal canal into the rectum to initiate defaecation.~Two alternative irrigation systems based on volume delivered exist: low-volume irrigation system depending on the manufacturer delivers approximately between 110ml to 300ml per irrigation and high-volume irrigation system delivers between 300ml to 1500ml per irrigation.
Study NCT05021003 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pressure biofeedback
Description: : Core stabilization training with pressure biofeedback unit
Study NCT05021003 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: core stabilization exercises
Description: : Core stabilization training without pressure biofeedback unit
Study NCT06189404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tigulixostat
Description: 300 mg oral dose
Study NCT06189404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theophylline
Description: 400 mg oral dose
Study NCT06547372 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention on Atopy
Description: The primary aim of this dietary intervention study is to assess the effectiveness of a dietary pattern characterized by lower saturated fats, higher wholegrains, fruit, and vegetables in reducing the severity of AD in young Singapore adults, as measured by changes in Scoring Atopic Dermatitis (SCORAD) scores, over a 2-month intervention period.
Study NCT05988164 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eye Mask
Description: Patients in the intervention group will be given eye masks and asked to sleep with them at 22:00 or earlier.
Study NCT05977920 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Caffeine
Description: s. description
Study NCT06081335 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EdgeEndo x7 continuous rotation files
Description: endodontic files operating in continuous rotation
Study NCT06081335 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EdgeOne Fire reciprocating files
Description: endodontic files operating in reciprocating motion
Study NCT05431634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental drug: ESK-001
Description: Multiple doses of ESK-001
Study NCT05431634 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06539975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Evening Primrose Oil 1000 MG
Description: Evening primrose oil 1000mg vaginally plus misoprostal for induction of labor
Study NCT06539975 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Evening Primrose Oil 1000 MG
Description: Evening primrose oil 1000mg vaginally plus misoprostal for induction of labor
Study NCT05696561 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Canaloplasty Device
Description: Canaloplasty
Study NCT05696314 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transoral Ultrasound
Description: The oropharynx is scanned using high-frequency, small-footprint ultrasound transducers placed onto the suspected oropharynx sub-locations (e.g. tonsils or tongue base). Lidocaine spray or gel will be applied prior to scanning to reduce the gag reflex.